Keywords: Takeda, Actos, Bladder cancer risk, USA, FDA, Warning

Bladder cancer risk of Takeda’s Actos now highlighted by US FDA

Article | 16 June 2011

Print This

The latest bad news for Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502) came last night with a warning from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in